Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C6H4O7.C5H14NO.Fe |
| Molecular Weight | 348.108 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Fe+3].C[N+](C)(C)CCO.[O-]C(=O)CC([O-])(CC([O-])=O)C([O-])=O
InChI
InChIKey=YJBFEDKRBVBHSN-UHFFFAOYSA-K
InChI=1S/C6H7O7.C5H14NO.Fe/c7-3(8)1-6(13,5(11)12)2-4(9)10;1-6(2,3)4-5-7;/h1-2H2,(H,7,8)(H,9,10)(H,11,12);7H,4-5H2,1-3H3;/q-1;+1;+3/p-3
DescriptionCurator's Comment: description was created based on several sources, including:
http://www.druginfosys.com/drug.aspx?drugcode=1316&type=1 | http://www.vademecum.es/medicamento-podertonic+adultos_3181
Curator's Comment: description was created based on several sources, including:
http://www.druginfosys.com/drug.aspx?drugcode=1316&type=1 | http://www.vademecum.es/medicamento-podertonic+adultos_3181
Ferrocholinate is a chelate prepared by reacting equal quantities of freshly precipitated ferric chloride with choline dihydrogen citrate. Ferrocholinate is used as a source of iron in iron deficiency anemia. Ferrocholinate absorption is increased by simultaneous administration of ascorbic acid. Absorption reduced by antacids, cholestyramine or proton pump inhibitors (omeprazole, pantoprazole, lansoprazole). The following adverse effects may occur: occasionally, gastrointestinal disorders (stomach pain, nausea, constipation or diarrhea) may appear, which usually disappear quickly after the dose is reduced or, if necessary, after treatment discontinuation. Darkness of stool: it is frequently observed during treatment and is safe for the patient. Allergic reactions may occur, also.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: GO:0020027 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | FERROLIP Approved UseFerrocholinate is primarily indicated in conditions like iron deficiency anaemia. Launch Date-2.86934401E11 |
|||
| Primary | FERROLIP Approved UseTreatment of iron deficiency states and iron deficiency anemia in adults and children, for deficient iron absorption, chronic bleeding or in situations where there is an increase of iron demands such as pregnancy or breastfeeding. Launch Date-2.86934401E11 |
|||
| Primary | FERROLIP Approved UseTreatment of iron deficiency states and iron deficiency anemia in adults and children, for deficient iron absorption, chronic bleeding or in situations where there is an increase of iron demands such as pregnancy or breastfeeding. Launch Date-2.86934401E11 |
Sample Use Guides
In Vivo Use Guide
Curator's Comment: http://www.ndrugs.com/?s=podertonic%20ni%C3%B1os | https://clicks.co.za/chela-fer_iron-supplement-30-tablets/p/44856 | https://www.aemps.gob.es/cima/pdfs/es/ft/54556/54556_ft.pdf
1 tablet (100 mg) daily Adults daily dose is equivalent to 112.6 mg Fe3. Take this medication preferably a few hours before meals. Duration of treatment depends on nature and severity of iron deficiency.
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
76966607
Created by
admin on Thu Jul 06 07:53:51 UTC 2023 , Edited by admin on Thu Jul 06 07:53:51 UTC 2023
|
PRIMARY | |||
|
0W21KB56NS
Created by
admin on Thu Jul 06 07:53:51 UTC 2023 , Edited by admin on Thu Jul 06 07:53:51 UTC 2023
|
PRIMARY |
PARENT (SALT/SOLVATE)
PARENT (SALT/SOLVATE)
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD
